Prostaglandin e1 derivatives
CA 2369662 A1 · Owner: Hirano, Hitomi · Inventors: Hirano, Hitomi; Yagi, Makoto; Tanami, Tohru
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Prostaglandin E1 derivatives represented by general formula (I) pharmaceutically acceptable salts thereof or hydrates of the same wherein A represents ethylene, vinylene, ethynylene O(CH2)q or S(O)r(CH2)q; R1 , represents C3-10 cycloalkyl (C1-4 alkyl)(C3-10 cycloalkyl), (C3-10 cycloalkyl)(C1-4 alkyl), C1-10 alkyl optionally substituted by hydroxy or C1-4 alkoxy, C2-10 alkenyl, optionally substituted by hydroxy or C1-4 alkoxy C2-10 , alkynyl, optionally substituted by hydroxy or C1-4 alkoxy or crosslinked , hydrocarbyl; R2 represents a hydrogen atom C1-10 alkyl or C3-10 cycloalkyl; m , is an integer of from 1 to 5; n is an integer of from 1 to 4; p is 0 1 or 2; , q is an integer of from 1 …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 7, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 7, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 7, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.